<SEC-DOCUMENT>0001213900-24-032740.txt : 20240415
<SEC-HEADER>0001213900-24-032740.hdr.sgml : 20240415
<ACCEPTANCE-DATETIME>20240415080018
ACCESSION NUMBER:		0001213900-24-032740
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20240415
FILED AS OF DATE:		20240415
DATE AS OF CHANGE:		20240415

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		24843138

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0203886-6k_immuron.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 6-K</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the Month of April 2024</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File Number: 001-38104</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>IMMURON LIMITED</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name of Registrant)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
&#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMURON LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXPLANATORY NOTE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron Limited (the &ldquo;Company&rdquo;) published
one announcement (the &ldquo;Public Notices&rdquo;) to the Australian Securities Exchange on April 15, 2024 titled:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Immuron
to host Live Virtual Event&rdquo;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 273pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the Public Notice is attached as an exhibit to this report
on Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    </B><BR>
    <B>Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea020388601ex99-1_immuron.htm">Immuron to host Live Virtual Event</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMURON LIMITED</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><IMG SRC="image_001.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 15, 2024</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Secretary</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea020388601ex99-1_immuron.htm
<DESCRIPTION>IMMURON TO HOST LIVE VIRTUAL EVENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immuron
to host Live Virtual Event</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melbourne,
Australia, April 15, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company
is pleased to advise our Chief Executive Officer, Steven Lydeamore together with our Chief Scientific Officer, Dr. Jerry Kanellos and
Research &amp; Development Manager, Dr. Joanne Casey will be hosting a Live Virtual Event on Tuesday, April 30 at 10am AEST / Monday,
April 29 at 8pm EST.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRAVELAN<SUP>&reg;
</SUP>BOUND FOR PHASE 3 CLINICAL TRIALS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exploring
Immuron&rsquo;s Positive Phase 2 Travelan&reg; Results and Upcoming Phase 3 Trial</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We&rsquo;d
like to invite shareholders and potential investors to Immuron Ltd&rsquo;s (ASX:IMC) / (NASDAQ:IMRN) upcoming Virtual Symposium!</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Join
Steve Lydeamore, CEO Immuron, Dr. Joanne Casey, R&amp;D Manager Immuron, and Dr. Jerry Kanellos, COO Immuron, as they explore the Company&rsquo;s
positive Phase 2 Travelan&reg; (IMM-124E) results, upcoming Phase 3 trial, proprietary technology behind Immuron&rsquo;s success, and
more.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Last
month, Immuron, a globally integrated biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for
the treatment of gut mediated diseases, reported positive interim topline results from its Phase 2 trial of Travelan. The study&rsquo;s findings
indicated protective efficacy against enterotoxigenic Escherichia coli (ETEC)-induced diarrhea, a common and debilitating condition affecting
travelers, and adds additional data to the established excellent safety and tolerability profile of Travelan. Remarkably, there was a
83.3% reduction in the number of participants requiring early antibiotic treatment compared to placebo and 100% of participants requiring
IV fluids were in the placebo group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron&rsquo;s
proprietary technology platform combines the natural human nutrition &amp; health benefits of bovine colostrum with a novel class of
specifically targeted oral polyclonal antibodies that offer delivery within the gastrointestinal tract and can be used to target viruses
or bacteria and neutralize the toxins they produce at mucosal surfaces.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the clinical study, predominantly funded by a US$3.43 million grant from the US Department of Defense, Travelan demonstrated a 36.4%
reduction in cases of moderate to severe diarrhea and a remarkable 66.7% efficacy against severe diarrhea instances, compared to placebo.
This Phase 2 clinical trial was a randomized, double-blind, placebo-controlled study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
30% to 70% of travelers experiencing traveler&rsquo;s diarrhea, according to the CDC, the traveler&rsquo;s diarrhea treatment market
is large and growing at a CAGR of ~7%. According to a Lumanity Opportunity Assessment for IMM-124E, based on the estimated market size
and pricing, the base case yearly revenue in USA for IMM-124E is projected at US$102M.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
will now proceed to hold an end of Phase 2 meeting with the FDA to discuss the pivotal Phase 3 registration strategy as well as explore
funding for Phase 3. By merely entering Phase 3, Immuron will be among an exclusive list of ASX biotech stocks in Phase 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
this webinar, you can expect an insightful exploration into the results, upcoming milestones to come from Immuron, and other research
and development pathways the Company is pursuing as it works to realize the full potential of its proprietary technology platform.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hope to see you on Tuesday, April 30 at 10am AEST / April 29 at 8pm ET.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Register
Today:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>https://www.linkedin.com/events/7180999382673018882/about/</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
release has been authorised by the directors of Immuron Limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
- - END - - -</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_002.jpg" ALT="">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 41px; width: 150px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY CONTACT:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Steven
Lydeamore</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">steve@immuron.com</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Immuron</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of infectious diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Travelan<SUP>&reg;</SUP></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Travelan&reg;
is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers&rsquo; diarrhea,
<FONT STYLE="background-color: white">a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce</FONT>.
Travelan&reg; is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with
meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers&rsquo; diarrhea. In Australia,
Travelan&reg; is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk
of Travelers&rsquo; Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan&reg; is
a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers&rsquo; Diarrhea. In the U.S., Travelan&reg;
is sold as a dietary supplement for digestive tract protection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Travelers&rsquo;
diarrhea (TD)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TD
is generally defined as the passage of &ge; 3 unformed stools per 24 hours plus at least one additional symptom (such as nausea, vomiting,
abdominal cramps, fever, blood/mucus in the stools, or fecal urgency) that develop while abroad or within 10 days of returning from any
resource-limited destinations (Leung et al., 2006). Diarrhea continues to be the most frequent health problem among travelers to destinations
in lower- and middle-income regions (Steffen, 2017). Deployed US military personnel, essentially representing a long-term traveller population,
are particularly affected given their population dynamics and the context in which they seek care and treatment (Connor et al., 2012).
Diarrhea is the leading infectious disease threat to the overall health and preparedness of deployed US armed forces, with diarrheagenic
E. coli, Campylobacter spp., and Shigella spp. among the most commonly reported etiologies (Riddle et al., 2006).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immuron
Platform Technology</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron&rsquo;s
proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has
the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can
withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal
(GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits directly
to the bacteria found there. The underlying nature of Immuron&rsquo;s platform technology enables the development of medicines across
a large range of infectious diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal
tract and neutralize the toxins they produce.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 41px; width: 150px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMM-124E</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IMM-124E
was developed using Immuron&rsquo;s platform technology. IMM-124E is produced from the colostrum of birthing cattle that have been immunised
during pregnancy with a vaccine containing the outer antigens of multiple human derived ETEC. A total of 13 ETEC strains are used in
the vaccine to produce high levels of antibodies against selected surface antigens from the most common strains of ETEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
resultant hyperimmune colostrum IMM-124E from ETEC vaccinated cows contains significant levels of polyclonal antibodies specific for
ETEC antigens LPS, CFA-I and Flagellin (Sears et al., 2017).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
antibodies produced in IMM-124E have been found to have a stronger binding and neutralizing activity (than the antibodies of unvaccinated
cattle) against a wide range of LPS antigens including both the variable O-polysaccharide region and the preserved oligosaccharide core
&lsquo;R&rsquo; region of LPS from the 13 serotypes used in the ETEC vaccine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IMM-124E
is manufactured into a tablet form referred to as Travelan<SUP>&reg;</SUP>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>References</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Connor
P, Porter CK, Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin Infect
Dis. 25(5): 546-54; 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leung
AK, Robson WL, Davies HD. Travelers&rsquo; diarrhea. Adv Ther. Jul-Aug; 23(4): 519-27; 2006</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Otto
W, Najnigier B, Stelmasiak T and Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum
to prevent diarrhea caused by enterotoxigenic Escherichia coli in volunteers Scandinavian Journal of Gastroenterology 46: 862&ndash;
868; 2011.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Riddle
MS, Sanders JW, Putnam SD, and Tribble DR. Incidence, etiology, and impact of diarrhea among long-term travelers&rsquo; (US military
and similar populations): A systematic review. American Journal of Tropical Medicine and Hygiene. 74(5): 891-900; 2006.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sears
KT, Tennant SM, Reymann MK, Simon R, Konstantopolos N, Blackwelder WC, Barry EM and Pasetti MF. Bioactive Immune Components of Anti-Diarrheagenic
Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum products. Clinical and Vaccine Immunology. 24 (8) 1-14; 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steffen
R. Epidemiology of travelers&rsquo; diarrhea. J Travel Med. 24(suppl_1): S2-S5; 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information visit: https://www.immuron.com.au/ and https://www.travelan.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscribe
for Immuron News: Here</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORWARD-LOOKING
STATEMENTS:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release may contain &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements
relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking
statements are based on management&rsquo;s current expectations and are subject to risks and uncertainties that could negatively affect
our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from
those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing
and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the
timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party
suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial
additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our
SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which
any such statement is based, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !$ #H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@!#T
MJM%<(UY-;EAYB -C_9/3]<U9/3BL+5[AM-U+3[TJ/(>3[+._=0WW#_WUQ^-
M&]134/6G4 %%%% !1110 50U73X=4TNXL)]PCGC*%EZKZ$>X."/I5^FN-PQQ
M^- &)X9U*:]TPPWF!?V;FVNE_P!M?XOHRX8?6M:6XBB*>9(J;V"+N.,L>P]Z
MY?6C_P (]XFM==7Y;*\VV>H<\*<_NI3]"=I/HPJ3Q1=*NI^&K4C+7&J*0/\
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GVTA"C. &.3^M '5BB@44 %%%% !1110 4F!Z444  X7BEHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !* 0P# 2(  A$! Q$!_\0
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MH/Q7F\]8=;@0QL<>?",%?JO?\*V?$_Q+LM*(M]+5+VX*@F3=^[3(XZ=36?\
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MI[9:3FXL8+@@ R1JY [9&:\[T[XG32^(197\%M!:!W#S9.5"@G^@KO\ 2_\
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M*OOJG_H0KC/A!_R%M2_ZX+_Z%7:?$/\ Y$F^_P" ?^A"N+^$'_(4U+_K@O\
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M4H-6TNWOK=@T<R!N.Q[CZ@TL8KTZ<EM;_(,([5*D7O?_ #+E>&?$S_D=Y_\
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98Y&&&D8EG/XFM:BBLY2<G=LTC%15DC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !4 S$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;\1>'M"\--]J739#<23HIVQ1JC+C<>I8L*T(;LQ3>,M,B/[F"-IHP.B%XR6
M_'G\:YW2=:\,>#=-:P\(6DU]J%QP9G0EG/8DXR1[ 8KHM'T&\TOPAK-WJ1+:
ME?PR2S#J5^4X'UIRAR)N6E[6ON];MD2JPJ3C&CJHWNUMM:W]=C.^#RK_ &=J
MC8&[SD&?;;7;^(E5_#6IJP!'V63@_P"Z:XKX0HZ:9J>]&7,R?>&/X:[?7P3X
M=U( 9)M9.!_NFLL5_O3]5^AKA_\ =UZ/]3B/@^3_ &3J0SP)UQ_WS7I%><?"
M%'32]2#HRGSD^\,?PUZ/48S^/(K"_P &(4445R'2%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1T4#'%W/5F/XTVBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /J*BO%?^%J^(?[EE_P!^C_\ %4X?
M%?7QUAL3_P!LF_\ BJ^9_LO$>7WGUG]KX;S^X]HHKQD?%C7O^?>Q_P"_;?\
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M^3^]^E1T4 /\Z3^\:3S'_OG\Z;10 NYC_$?SI,GU-%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
A44 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
